MCM
CARM

Moore Capital Management’s Carisma Therapeutics CARM Stock Holding History

Moore Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,000
Closed -$195K – 290
2018
Q2 		$195K Buy
+5,000
New +$220K ﹤0.01% 245

Other funds holding CARM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Moore Capital Management's CARM Position: Q3 2018 in Review

Moore Capital Management sold out of Carisma Therapeutics (CARM) in Q3 2018, closing a stake of 5,000 shares — an estimated $195K sold.

Moore Capital Management first reported a position in CARM in Q2 2018 and held it in 1 quarter. The position peaked at $195K in Q2 2018. 47 funds tracked by Wall St. Rank hold CARM as of Q3 2018.

  • Moore Capital Management reported no remaining Carisma Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Moore Capital Management sold 5,000 Carisma Therapeutics shares in Q3 2018, an estimated $195K.
  • Moore Capital Management first reported a position in Carisma Therapeutics in Q2 2018 and held it in 1 quarter.
  • Moore Capital Management's Carisma Therapeutics position peaked at $195K in Q2 2018.
  • 47 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2018.

Based on Moore Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.